Colon Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Conditions
Brief summary
S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. 5-FU is metabolized by CYP2A6 and DPD. In this study, the researchers investigate the influences of differences in activities of CYP2A6 and DPD on pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes in digestive organ cancer patients treated with S-1.
Interventions
DRUGS-1
Sponsors
Hamamatsu University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Inclusion criteria
* Patients with digestive organ cancer
Exclusion criteria
* Patients without digestive organ cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whether the differences in activities of CYP2A6 and DPD affect pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect and motility of patients treated with S-1 | — |
Countries
Japan
Contacts
Primary ContactNaohito Shirai, MD., PhD
Outcome results
None listed